Correction: A european spectrum of pharmacogenomic biomarkers: Implications for clinical pharmacogenomics (PLoS ONE (2016) 11:9 (e0162866) DOI: 10.1371/journal.pone.0162866);A European spectrum of pharmacogenomic biomarkers: Implications for clinical pharmacogenomics

PLoS ONE

Volumn 11, Issue 9, 2016, Pages

  Mizzi, Clint ^a,b   Dalabira, Eleni ^c,ae   Kumuthini, Judit ^d   Dzimiri, Nduna ^e   Balogh, Istvan ^f   Başak, Nazli ^g   Böhm, Ruwen ^h   Borg, Joseph ^b   Borgiani, Paola ⁱ   Bozina, Nada ^j   Bruckmueller, Henrike ^h   Burzynska, Beata ^k   Carracedo, Angel ^l   Cascorbi, Ingolf ^h   Deltas, Constantinos ^m   Dolzan, Vita ⁿ   Fenech, Anthony ^b   Grech, Godfrey ^b   Kasiulevicius, Vytautas ^o   Kádaši, Ludevít ^p,q   Kučinskas, Vaidutis ^o   Khusnutdinova, Elza ^r,s   Loukas, Yiannis L ^t   Macek, Milan ^u   Makukh, Halyna ^v   Mathijssen, Ron ^a   Mitropoulos, Konstantinos ^w   Mitropoulou, Christina ^a   Novelli, Giuseppe ⁱ   Papantoni, Ioanna ^c   Pavlovic, Sonja ^x   Saglio, Giuseppe ^y   Setric, Jadranka ^j,z   Stojiljkovic, Maja ^x   Stubbs, Andrew P ^a   Squassina, Alessio ^aa   Torres, Maria ^l   Turnovec, Marek ^u   Van Schaik, Ron H ^a   Voskarides, Konstantinos ^m   Wakil, Salma M ^e   Werk, Anneke ^h   Zompo, Maria Del ^aa   Zukic, Branka ^x   Katsila, Theodora ^c   Lee, Ming Ta Michael ^ab,af   Motsinger Rief, Alison ^ac   Leod, Howard L Mc ^ad   Van Der Spek, Peter J ^a   Patrinos, George P ^a,c   more..

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF MALTA   (Malta)

^c UNIVERSITY OF PATRAS   (Greece)

^d Medical School   (South Africa)

^e KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^f UNIVERSITY OF DEBRECEN   (Hungary)

^g BOGAZICI UNIVERSITY   (Turkey)

^h UNIVERSITY OF KIEL   (Germany)

ⁱ UNIVERSITY OF ROME TOR VERGATA   (Italy)

^j KBC Zagreb   (Croatia)

^k INSTITUTE OF BIOCHEMISTRY AND BIOPHYSICS   (Poland)

^l UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^m UNIVERSITY OF CYPRUS   (Cyprus)

ⁿ UNIVERSITY OF LJUBLJANA   (Slovenia)

^o VILNIUS UNIVERSITY   (Lithuania)

^p Physics and Informatics   (Slovakia)

^q INSTITUTE OF CHEMISTRY   (Slovakia)

^r INSTITUTE OF BIOCHEMISTRY AND GENETICS   (Russian Federation)

^s Birsk Branch of Federal State Budgetary Educational Establishment of Higher Education Bashkir State University   (Russian Federation)

^t UNIVERSITY OF ATHENS   (Greece)

^u UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^v STATE INSTITUTION NATIONAL RESEARCH CENTER FOR RADIATION MEDICINE OF THE NATIONAL ACADEMY OF MEDICAL SCIENCES OF UKRAINE   (Ukraine)

^w Golden Helix Institute of Biomedical Research   (United Kingdom)

^x UNIVERSITY OF BELGRADE   (Serbia)

^y UNIVERSITY OF TURIN   (Italy)

^z UNIVERSITY OF ZAGREB   (Croatia)

^aa UNIVERSITY OF CAGLIARI   (Italy)

^ab RIKEN   (Japan)

^ac NORTH CAROLINA STATE UNIVERSITY   (United States)

^ad H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^ae LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^af GENOMIC MEDICINE INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; WARFARIN; ANTICOAGULANT AGENT; CYTOCHROME P450 2C9; GENETIC MARKER; VITAMIN K EPOXIDE REDUCTASE; VKORC1 PROTEIN, HUMAN;

ARTICLE; CONTROLLED STUDY; CYP2C19 GENE; CYP2C9 GENE; CYP3A5 GENE; EUROPEAN; GENE; GENE FREQUENCY; GENOTYPE; HUMAN; HUMAN EXPERIMENT; MEDICATION THERAPY MANAGEMENT; NORMAL HUMAN; PHARMACOGENOMICS; SLCO1B1 GENE; TPMT GENE; VKORC1 GENE; CLUSTER ANALYSIS; ETHNIC GROUP; EUROPE; GENETIC MARKER; GENETICS; PHARMACOGENETICS;

ANTICOAGULANTS; CLUSTER ANALYSIS; CYTOCHROME P-450 CYP2C9; ETHNIC GROUPS; EUROPE; GENETIC MARKERS; HUMANS; PHARMACOGENETICS; VITAMIN K EPOXIDE REDUCTASES; WARFARIN;

EID: 84992409620     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0172595     Document Type: Erratum

References (32)

1. Squassina A, Manchia M, Manolopoulos VG, Artac M, Lappa-Manakou C, Karkabouna S, et al. Realities and expectations of pharmacogenomics and personalized medicine: impact of translating genetic knowledge into clinical practice. Pharmacogenomics. 2010; 11(8):1149-1167 doi: 10.2217/pgs.10.97
2. Davies EC, Green CF, Mottram DR, Pirmohamed M. Interpreting adverse drug reaction (ADR) reports as hospital patient safety incidents. Br J Clin Pharmacol. 2010; 70(1):102-108. doi: 10.1111/j.1365-2125.2010.03671.x
3. Zineh I, Pacanowski MA. Pharmacogenomics in the assessment of therapeutic risks versus benefits: inside the United States Food and Drug Administration. Pharmacotherapy, 2011; 31(8):729-735. doi: 10.1592/phco.31.8.729
4. Ehmann F, Caneva L, Prasad K, Paulmichl M, Maliepaard M, Llerena A, et al. Pharmacogenomic information in drug labels: European Medicines Agency perspective. Pharmacogenomics J. 2015; 15 (3):201-210. doi: 10.1038/tpj.2014.86
5. Arnold FL, Fukunaga S, Kusama M, Matsuki N, Ono S. Assessment of factors associated with dose differences between Japan and the United States. Clin Pharmacol Ther. 2014; 95(5):542-549. doi: 10. 1038/clpt.2013.231
6. Wilson JF, Weale ME, Smith AC, Gratrix F, Fletcher B, Thomas MG, et al. Population genetic structure of variable drug response. Nat Genet. 2001; 29(3):265-269
7. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009; 461(7262):399-401. doi: 10.1038/nature08309
8. Roewer L, Croucher PJ, Willuweit S, Lu TT, Kayser M, Lessig R, et al. Signature of recent historical events in the European Y-chromosomal STR haplotype distribution. Hum Genet. 2005; 116:279-291.
9. Giardine B, Borg J, Higgs DR, Peterson KR, Philipsen S, Maglott D, et al. Systematic documentation and analysis of human genetic variation in hemoglobinopathies using the microattribution approach. Nat Genet. 2011; 43(4):295-301. doi: 10.1038/ng.785
10. Patrinos GP, Cooper DN, van Mulligen E, Gkantouna V, Tzimas G, Tatum Z, et al. Microattribution and nanopublication as means to incentivize the placement of human genome variation data into the public domain. Hum Mutat. 2012; 33(11): 1503-1512. doi: 10.1002/humu.22144
11. Weale ME. Quality control for genome-wide association studies. Methods Mol Biol, 2010; 628:341-72. doi: 10.1007/978-1-60327-367-1-19
12. Papadopoulos P, Viennas E, Gkantouna V, Pavlidis C, Bartsakoulia M, Ioannou ZM, et al. Developments in FINDbase worldwide database for clinically relevant genomic variation allele frequencies. Nucleic Acids Res. 2014; 42(Database issue):D1020-D1026. doi: 10.1093/nar/gkt1125
13. International Warfarin Pharmacogenetics Consortium, Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MT, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med. 2009; 360(8):753-764 doi: 10.1056/NEJMoa0809329
14. International HapMap Consortium. The International HapMap Project. Nature. 2003; 426(6968):789-796.
15. Ramsey LB, Johnson SG, Caudle KE, Haidar CE, Voora D, Wilke RA, et al. The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update. Clin Pharmacol Ther. 2014; 96(4):423-428. doi: 10.1038/clpt.2014.125
16. Wilke RA, Ramsey LB, Johnson SG, Maxwell WD, McLeod HL, Voora D, et al. The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin Pharmacol Ther. 2012; 92(1):112-117. doi: 10.1038/clpt.2012.57
17. Van Driest SL, Shi Y, Bowton EA, Schildcrout JS, Peterson JF, Pulley J, et al. Clinically actionable genotypes among 10, 000 patients with preemptive pharmacogenomic testing. Clin Pharmacol Ther. 2014; 95(4):423-431. doi: 10.1038/clpt.2013.229
18. Pritchard JK, Stephens M, Donnelly P. Inference of population structure using multilocus genotype data. Genetics, 2000; 155(2):945-959.
19. Limdi NA. Warfarin pharmacogenetics: challenges and opportunities for clinical translation. Front Pharmacol, 2012; 3:183. doi: 10.3389/fphar.2012.00183
20. Sosnay PR, Siklosi KR, Van Goor F, Kaniecki K, Yu H, Sharma N, et al. Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene. Nat Genet. 2013; 45 (10):1160-1167 doi: 10.1038/ng.2745
21. Bonifaz-Peña V, Contreras AV, Struchiner CJ, Roela RA, Furuya-Mazzotti TK, Chammas R, et al. Exploring the distribution of genetic markers of pharmacogenomics relevance in Brazilian and Mexican populations. PLoS One. 2014; 9(11):e112640 doi: 10.1371/journal.pone.0112640
22. Jittikoon J, Mahasirimongkol S, Charoenyingwattana A, Chaikledkaew U, Tragulpiankit P, Mangmool S, et al. Comparison of genetic variation in drug ADME-related genes in Thais with Caucasian, African and Asian HapMap populations. J Hum Genet. 2016; 61(2):119-127. doi: 10.1038/jhg.2015.115
23. Maisano Delser P, Fuselli S. Human loci involved in drug biotransformation: worldwide genetic variation, population structure, and pharmacogenetic implications. Hum Genet. 2013; 132(5):563-577. doi: 10.1007/s00439-013-1268-5
24. Ramos E, Doumatey A, Elkahloun AG, Shriner D, Huang H, Chen G, et al. Pharmacogenomics, ancestry and clinical decision making for global populations. Pharmacogenomics J. 2014; 14(3):217-222. doi: 10.1038/tpj.2013.24
25. Chen J, Teo YY, Toh DS, Sung C. Interethnic comparisons of important pharmacology genes using SNP databases: potential application to drug regulatory assessments. Pharmacogenomics. 2010; 11 (8):1077-1094. doi: 10.2217/pgs.10.79
26. Jackson JN, Long KM, He Y, Motsinger-Reif AA, McLeod HL, Jack J. A comparison of DMET Plus microarray and genome-wide technologies by assessing population substructure. Pharmacogenetics Genomics. 2016; in press.
27. Snyder SR, Mitropoulou C, Patrinos GP, Williams MS. Economic evaluation of pharmacogenomics: A value-based approach to pragmatic decision making in the face of complexity. Public Health Genomics. 2014; 17(5-6):256-264 doi: 10.1159/000366177
28. Potamias G, Lakiotaki K, Katsila T, Lee MT, Topouzis S, Cooper DN, et al. Deciphering next-generation pharmacogenomics: An information technology perspective. Open Biol. 2014; 4(7). pii:140071.
29. Kampourakis K, Vayena E, Mitropoulou C, Borg J, van Schaik RH, Cooper DN, et al. Key challenges for next generation pharmacogenomics. EMBO Rep 2014; 15(5):472-476.
30. Mitropoulou C, Mai Y, van Schaik RH, Vozikis A, Patrinos GP. Documentation and analysis of the policy environment and key stakeholders in pharmacogenomics and genomic medicine in Greece. Public Health Genomics 2014; 17(5-6):280-286.
31. Mizzi C, Peters B, Mitropoulou C, Mitropoulos K, Katsila T, Agarwal MR, et al Personalized pharmacogenomics profiling using whole-genome sequencing. Pharmacogenomics. 2014; 15(9):1223-1234. doi: 10.2217/pgs.14.102
32. Schildcrout JS, Denny JC, Bowton E, Gregg W, Pulley JM, Basford MA, et al. Optimizing drug outcomes through pharmacogenetics: A case for preemptive genotyping. Clin Pharmacol Ther. 2012; 92 (2):235-242. doi: 10.1038/clpt.2012.66